… Another study revealed that in N2 patients with stage IIIa disease and EGFR mutation, the
observation group had even longer median DFS (49 vs. 30 months; P = .195) and OS (59 vs. …

… diagnosed as stage III adenocarcinoma without lymph node biopsies. The diagnosis of N
stage was clinically … In conclusion, concurrent CRT gave shorter PFS in EGFR-mutated stage III …

… phase II and III trials of patients whose disease had progressed with an early-generation
EGFR-… In a phase III trial of patients with EGFR mutation-positive advanced NSCLC (FLAURA […

… EGFR-TKI with demonstrated efficacy in NSCLC, including in the CNS. The primary DFS
analysis of the phase III … in patients with EGFR-mutated stage IB-IIIA NSCLC after complete …

… Second, the number of patients who underwent EGFR mutation screening during the early
stages of their disease, especially stage IIA and IIB, was small, which may have affected our …

… with high-risk (ie, stage III) NSCLC, which is consistent with trials … stage IIIA NSCLC and
also suggests that EGFR TKI therapy could be an appropriate adjuvant therapy in EGFR mutation…

… CTONG 1103 was a national, multicenter, open-label, phase II, randomized controlled trial
… stage IIIA-N2 NSCLC with EGFR mutations in exon 19 or 21 (EMERGING); EGFR mutation …

… improvement in DFS in patients with stage IB-IIIA EGFR-mutant NSCLC (HR, 0.20; … stage
II-IIIA (N1-N2) EGFR-mutant NSCLC may be changed from adjuvant therapy to adjuvant EGFR…

… unresectable EGFRm stage III NSCLC. We outline the rationale for investigating EGFR-TKI …
gaps and future challenges for treating patients with unresectable EGFRm stage III NSCLC. …

… 19 deletion (Del) tended to have a longer survival after BM than the non-EGFR 19 Del group
(… data suggested EGFR mutation to be one of the predictors for subsequent BM in stage I-III …